Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APC101 in Postherpetic Neuralgia
NCT07599800Phase 3Not yet recruiting
- Sponsor
- Andros Pharmaceuticals Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of APC101 in postherpetic neuralgia (PHN), sponsored by Andros Pharmaceuticals Co., Ltd.. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
APC101
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT07599800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599800.